Patents by Inventor Richard Simon Todd

Richard Simon Todd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
    Publication number: 20230100842
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Application
    Filed: August 24, 2022
    Publication date: March 30, 2023
    Applicant: Ligand UK Development Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • Solid forms of a plasma kallikrein inhibitor and salts thereof
    Patent number: 11584735
    Abstract: New solid forms of the plasma kallikrein inhibitor, 1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide and its salts, are described.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: February 21, 2023
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: David Malcolm Crowe, Edwin Aret, Kiran Gandhi, Ruben Henricus Carolus Adrianus Titus Lelieveld, Emma Kay Sharp, Richard Simon Todd
  • Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists
    Patent number: 11466019
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: October 11, 2022
    Assignee: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • Dosage forms comprising a plasma kallikrein inhibitor
    Patent number: 11234939
    Abstract: The present invention relates to oral solid dosage forms comprising a plasma kallikrein inhibitor, in particular a solid form (Form 1) of the compound of Formula A. Also provided are methods of preparing oral solid dosage forms comprising the compound of Formula A using Form 1 of the compound of Formula A.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: February 1, 2022
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: John Herman Collett, Gary Paul Cook, Jamie Joseph Farrar, Michael John Frodsham, Michael Bryan Roe, Richard Simon Todd, Robert Neil Ward
  • SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF
    Publication number: 20210171496
    Abstract: New solid forms of the plasma kallikrein inhibitor, 1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide and its salts, are described.
    Type: Application
    Filed: November 29, 2018
    Publication date: June 10, 2021
    Inventors: David Malcolm CROWE, Stephen Mark MACDONALD-BROWN, Edwin ARET, Kiran GANDHI, Ruben Henricus Carolus Adrianus Titus LELIEVELD, Emma Kay SHARP, Richard Simon TODD
  • TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
    Publication number: 20210115054
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Application
    Filed: November 3, 2020
    Publication date: April 22, 2021
    Applicant: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists
    Patent number: 10875868
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: December 29, 2020
    Assignee: VERNALIS (R&D) LIMITED
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • DOSAGE FORMS COMPRISING A PLASMA KALLIKREIN INHIBITOR
    Publication number: 20200345647
    Abstract: The present invention relates to oral solid dosage forms comprising a plasma kallikrein inhibitor, in particular a solid form (Form 1) of the compound of Formula A. Also provided are methods of preparing oral solid dosage forms comprising the compound of Formula A using Form 1 of the compound of Formula A.
    Type: Application
    Filed: November 28, 2018
    Publication date: November 5, 2020
    Inventors: John Herman COLLETT, Gary Paul COOK, Jamie Joseph FARRAR, Michael John FRODSHAM, Michael Bryan ROE, Richard Simon TODD, Robert Neil WARD
  • TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
    Publication number: 20200172547
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Application
    Filed: December 2, 2019
    Publication date: June 4, 2020
    Applicant: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
    Patent number: 10538526
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Grant
    Filed: September 15, 2018
    Date of Patent: January 21, 2020
    Assignee: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
    Publication number: 20190031668
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Application
    Filed: September 15, 2018
    Publication date: January 31, 2019
    Applicant: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
    Patent number: 10106547
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: October 23, 2018
    Assignee: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
    Publication number: 20170342081
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Application
    Filed: August 21, 2017
    Publication date: November 30, 2017
    Applicant: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
    Patent number: 9765080
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: September 19, 2017
    Assignee: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
    Publication number: 20170088552
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Application
    Filed: June 2, 2016
    Publication date: March 30, 2017
    Applicant: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
    Patent number: 9376443
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: June 28, 2016
    Assignee: VERNALIS (R&D) LIMITED
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
    Publication number: 20150291602
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Application
    Filed: February 10, 2015
    Publication date: October 15, 2015
    Applicant: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antagonists
    Patent number: 8987279
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: March 24, 2015
    Assignee: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
    Publication number: 20130245044
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Application
    Filed: May 8, 2013
    Publication date: September 19, 2013
    Applicant: Vernalis Research Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
  • Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists
    Patent number: 8450328
    Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: May 28, 2013
    Assignee: Vernalis (R&D) Limited
    Inventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd